Ftse Mib
33.736,40
-0,03%
DAX
17.896,50
-0,14%
S&P 500
5.064,20
0,91%
NASDAQ
15.840,96
1,51%
Bitcoin
59.291,27
0,29%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ PepGen Inc (PEPG) PepGen Inc (PEPG) Notizie

PepGen Inc

PEPG
14,49
0,59 (4,24%)
02 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
13/3/202421:05GLOBEPepGen to Participate in Upcoming Investor Conferences
13/3/202412:00GLOBEPepGen Receives U.S. FDA Orphan Drug and Rare Pediatric..
06/3/202422:23EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
06/3/202422:01GLOBEPepGen Reports Fourth Quarter and Full Year 2023 Financial..
06/3/202422:00EDGAR2Form 8-K - Current report
04/3/202413:27EDGAR2Form 8-K - Current report
04/3/202413:00GLOBEPepGen Announces Clearance of CTA by UK Medicines &..
01/3/202423:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202423:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202423:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202414:00EDGAR2Form 8-K - Current report
20/2/202414:00GLOBEPepGen Receives U.S. FDA Fast Track Designation for..
07/2/202422:55EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
07/2/202413:36EDGAR2Form 8-K - Current report
07/2/202413:30GLOBEPepGen Announces Pricing of $80.1 Million Underwritten..
17/1/202414:00EDGAR2Form 8-K - Current report
17/1/202413:00GLOBEMary Beth DeLena Joins PepGen as General Counsel and..
08/1/202413:00EDGAR2Form 8-K - Current report
08/1/202413:00GLOBEPepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase..
18/12/202314:00EDGAR2Form 8-K - Current report
18/12/202314:00GLOBEPepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1..
15/11/202314:00EDGAR2Form 8-K - Current report
15/11/202314:00GLOBEPepGen Announces Appointment of Howard Mayer, M.D. to Board..
08/11/202314:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202314:00EDGAR2Form 8-K - Current report
08/11/202314:00GLOBEPepGen Reports Third Quarter 2023 Financial Results and..
12/10/202313:52DJNFDA Lifts Hold on PepGen's New Drug Application for..
12/10/202313:05EDGAR2Form 8-K - Current report
12/10/202313:00GLOBEPepGen Inc. Announces FDA has Lifted the Clinical Hold on..
27/9/202322:16GLOBEPepGen Announces Upcoming Presentations at the 28th Annual..
06/9/202322:06EDGAR2Form 8-K - Current report
06/9/202322:05GLOBEPepGen Inc. Announces Clearance of CTA by Health Canada to..
06/9/202314:16EDGAR2Form 8-K - Current report
06/9/202314:00GLOBEPepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting..
01/9/202314:00GLOBEPepGen Announces Presentations at the 2023 Myotonic..
08/8/202314:49EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
08/8/202314:27EDGAR2Form 8-K - Current report
08/8/202314:17EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202314:15EDGAR2Form 8-K - Current report
08/8/202314:15GLOBEPepGen Reports Second Quarter 2023 Financial Results and..
13/6/202323:07DJNPepGen Withdraws Guidance on Launch of Study for Muscle..
13/6/202322:05GLOBEPepGen Inc. Provides Update on Planned Initiation of Phase 1..
30/5/202323:24DJNPepGen Shares Tumble 18.4% After FDA Issues Hold Notice on..
30/5/202322:05GLOBEPepGen Inc. Announces Clinical Hold in the U.S. on IND..
18/5/202313:00GLOBEPepGen Announces Clearance by Health Canada of CTA for..
11/5/202313:00GLOBEPepGen Reports First Quarter 2023 Financial Results and..
04/5/202314:00GLOBEPepGen to Participate in the Bank of America Securities 2023..
Apertura: 14,00 Min: 13,41 Max: 14,59
Chiusura: 13,90

La tua Cronologia

NASDAQ
PEPG
PepGen
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network